Ben Hirschler

AstraZeneca in partnering talks for Alzheimer’s drug

May 14, 2019 at 6:00 a.m.

By Ben Hirschler LONDON (Reuters) - AstraZeneca, fighting a $106 billion bid approach from Pfizer, is talking to other companies as it seeks a partnering deal for its experimental Alzheimer's...

Astra gets lift in Pfizer fight as U.S. okays heart pill

May 14, 2019 at 6:00 a.m.

By Ben Hirschler LONDON (Reuters) - AstraZeneca Plc has won U.S. approval for Epanova, a new pill for heart disease, providing a welcome - but relatively minor - piece of...

Poor lung drug sales hit GSK in first-quarter, CEO wary on M&A

August 25, 2021 at 4:30 a.m.

LONDON (Reuters) - GlaxoSmithKline posted a 10 percent fall in quarterly sales on Wednesday, highlighting some of the industry pressures behind last week's decision to trade more than $20 billion...

GSK says staying on sidelines in Astra, Pfizer fight

August 25, 2021 at 4:30 a.m.

LONDON (Reuters) - GlaxoSmithKline is just an "interested observer" as U.S. drugmaker Pfizer battles to win British rival AstraZeneca in a potential $100 billion deal, GSK's chief executive said on...

New kind of trial aims to speed cancer drug development

August 25, 2021 at 4:02 a.m.

LONDON (Reuters) - Scientists and drugmakers are pioneering a new kind of clinical trial that changes the way cancer drugs are studied, potentially cutting both the time and cost of...

New kind of trial aims to speed cancer drug development

May 14, 2019 at 5:54 a.m.

LONDON (Reuters) - Scientists and drugmakers are pioneering a new kind of clinical trial that changes the way cancer drugs are studied, potentially cutting both the time and cost of...

GSK faces criminal bribery investigation in Poland

August 25, 2021 at 3:58 a.m.

LONDON/WARSAW (Reuters) - GlaxoSmithKline is facing a criminal investigation in Poland for allegedly bribing doctors to promote its lung drug Seretide, adding to problems for a company already accused of...

Doctors welcome hepatitis C drug rivals, Gilead still leads

August 25, 2021 at 3:53 a.m.

LOS ANGELES/LONDON (Reuters) - Doctors at a key medical conference welcomed the prospect of more new drugs to treat the liver-destroying hepatitis C virus, while agreeing that Gilead Sciences Inc...

Doctors welcome hepatitis C drug rivals, Gilead still leads

May 14, 2019 at 5:52 a.m.

LOS ANGELES/LONDON (Reuters) - Doctors at a key medical conference welcomed the prospect of more new drugs to treat the liver-destroying hepatitis C virus, while agreeing that Gilead Sciences Inc...

WHO joins clamor to make new hepatitis C pills affordable

August 25, 2021 at 3:52 a.m.

LONDON (Reuters) - The World Health Organization wants a "concerted effort" to drive down the cost of new hepatitis C drugs that offer a cure for the liver-destroying virus but...

All Stories